The Path from Biomarker Discovery to Regulatory Qualification
Editat de Federico Goodsaid, William B. Mattesen Limba Engleză Paperback – 12 sep 2013
For complimentary access to chapter 13, 'Classic' Biomarkers of Liver Injury, by John R. Senior, Associate Director for Science, Food and Drug Administration, Silver Spring, Maryland, USA, please visit the following site: http://tinyurl.com/ClassicBiomarkers
- Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science
- Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use
- Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities
Preț: 260.45 lei
Preț vechi: 345.29 lei
-25% Nou
Puncte Express: 391
Preț estimativ în valută:
49.84€ • 52.17$ • 41.48£
49.84€ • 52.17$ • 41.48£
Carte tipărită la comandă
Livrare economică 24 martie-07 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780123914965
ISBN-10: 0123914965
Pagini: 206
Ilustrații: Illustrated
Dimensiuni: 152 x 229 x 10 mm
Greutate: 0.41 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0123914965
Pagini: 206
Ilustrații: Illustrated
Dimensiuni: 152 x 229 x 10 mm
Greutate: 0.41 kg
Editura: ELSEVIER SCIENCE
Public țintă
The primary audience includes pharmaceutical scientists and pharmacologists, clinicians and drug development managers and executives involved in pharmaceutical development.Cuprins
1. Biomarker Applications in the Pharmaceutical Industry
2. The Impact of Biomarker Qualification Regulatory Processes on the Critical Path for Drug Development
3. Regulatory Experience at the EMA
4. Regulatory Experience at the PMDA
Section 1: Biomarker Development and Qualification in the Pharmaceutical Industry
5. Pfizer
6. Astra Zeneca
7. Novartis
8. BMS
9. CTCs
Section 2: Toxicogenomic Biomarkers
10. Gene Logic
11. Johnson and Johnson
12. ILSI-HESI
Section 3: Biomarkers of Drug Safety
13. “Classic Markers of Liver Injury
14. Urinary Biomarkers of Kidney Injury
Section 4: Consortia
15. ILSI-HESI
16. C-Path Institute
17. Beyond QT
Section 5: Path to Regulatory Qualification Process Development
18. FDA
19. PMDA
20. The tortuous path from development to qualification of biomarkers
2. The Impact of Biomarker Qualification Regulatory Processes on the Critical Path for Drug Development
3. Regulatory Experience at the EMA
4. Regulatory Experience at the PMDA
Section 1: Biomarker Development and Qualification in the Pharmaceutical Industry
5. Pfizer
6. Astra Zeneca
7. Novartis
8. BMS
9. CTCs
Section 2: Toxicogenomic Biomarkers
10. Gene Logic
11. Johnson and Johnson
12. ILSI-HESI
Section 3: Biomarkers of Drug Safety
13. “Classic Markers of Liver Injury
14. Urinary Biomarkers of Kidney Injury
Section 4: Consortia
15. ILSI-HESI
16. C-Path Institute
17. Beyond QT
Section 5: Path to Regulatory Qualification Process Development
18. FDA
19. PMDA
20. The tortuous path from development to qualification of biomarkers
Recenzii
"This book focuses on the use of biomarkers in drug development, for efficacy and targeted drug therapy as well as for predicting drug harm. It is a collection of papers that present the authors' examples of their work using biomarkers, not only for drug development but also for regulatory review." --Doody.com, January 3, 2014
"Scientists from academia, drug companies, and regulatory agencies explore ways to develop biomarkers and integrate them in both developing and regulating drugs. They cover the impact of biomarker qualification regulatory processes on the critical path for drug development, biomarker development and qualification in the pharmaceutical industry, toxicogenomic biomarkers, biomarkers of drug safety, consortia, and the path to regulatory qualification process development." --Reference and Research Book News, December 2013
"Scientists from academia, drug companies, and regulatory agencies explore ways to develop biomarkers and integrate them in both developing and regulating drugs. They cover the impact of biomarker qualification regulatory processes on the critical path for drug development, biomarker development and qualification in the pharmaceutical industry, toxicogenomic biomarkers, biomarkers of drug safety, consortia, and the path to regulatory qualification process development." --Reference and Research Book News, December 2013